Pharmena S.A.

Warsaw Stock Exchange PHR.WA

Pharmena S.A. EBIT Margin for the year ending December 31, 2023: 358.11%

Pharmena S.A. EBIT Margin is 358.11% for the year ending December 31, 2023, a 9,972.34% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Pharmena S.A. EBIT Margin for the year ending December 31, 2022 was -3.63%, a 86.67% change year over year.
  • Pharmena S.A. EBIT Margin for the year ending December 31, 2021 was -27.22%, a 55.15% change year over year.
  • Pharmena S.A. EBIT Margin for the year ending December 31, 2020 was -60.69%, a 34.55% change year over year.
  • Pharmena S.A. EBIT Margin for the year ending December 31, 2019 was -92.73%, a -13,686.37% change year over year.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
SV Wall Street
Warsaw Stock Exchange: PHR.WA

Pharmena S.A.

CEO Mr. Konrad Palka
IPO Date Aug. 1, 2008
Location Poland
Headquarters ul. Wólczanska 178
Employees 15
Sector Health Care
Industries
Pharmaceuticals Biotechnology Cosmetics
Description

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.

StockViz Staff

January 31, 2025

Any question? Send us an email